IMRESPDX

Breast Cancer

• ATLAS (2013): 10y vs. 5y tamoxifen in breast cancer

• EMILIA (2012): T-DM1 in metastatic breast cancer

• HERA (2005): Trastuzumab in breast cancer

• NSABP B-32 (2010): Sentinel LN biopsy in breast cancer

• STAR (2006): Tamoxifen vs. raloxifene in breast cancer prevention

Deep Vein Thrombosis

• New England Journal of Medicine (2025): Cancer Associated VTE

Lung Cancer

• Nivolumab vs docetaxel for Advanced NSCLC

• AZD9291 (osemertinib) for EGFR-inh resistant NSCLC

• Early Palliative Care (2010): Palliative care in NSCLC

• NLST (2011): CT vs. CXR in lung cancer screening

• PARAMOUNT (2013): Maintenance pemetrexed in lung cancer

Melanoma

• Pembrolizumab vs ipilimumab for Malignant Melanoma

• BRIM-3 (2011): Vemurafenib in BRAF V600+ melanoma

• CheckMate-003 (2012): Nivolumab in solid tumors

Prostate Cancer

• Enzalutamide maintenance after chemo NEJM 2012

• Enzalutamide in metastatic prostate cancer before chemo NEJM 2014

• Abiraterone and increased survival NEJM 2011

• Radium-223 and survival in prostate cancer NEJM 2013

• Sipuleucel-T immunotherapy for castrate-resistant prostrate cancer NEJM 2010

• Chemohormonal therapy in metastatic hormone-sensitive prostate cancer NEJM 2015

Renal Cell Carcinoma

• CheckMate-003 (2012): Nivolumab in solid tumors

• SWOG 8949 (2001): Cytoreductive nephrectomy in metastatic RCC

Colorectal Cancer

• MOSAIC trial (2009): Add adjuvant oxaliplatin to 5FU and Leucovorin for Stage II and III CRC

• FOLFOX Trial (2004) NEJM

• Capecitabine as adjuvant treatment for stage III CRC (2005) NEJM

• Subgroup Analysis 5FU + oxaliplatin for stage II or elderly (70-75 yrs)

• Identification of Lynch syndrome among patients with CRC (2012) JAMA

Palliative Care

• Chemotherapy Near the End of Life from Dr. Fromme at OHSU

• Suicide and Cardiovascular Death after Cancer Diagnosis NEJM

• Chemotherapy Use, Performance Status, and Quality of Life at the End of Life

• Early Palliative Care (2010): Palliative care in NSCLC